Luo, Qingwei
Lew, Jie-Bin
Steinberg, Julia
Worthington, Joachim
Yu, Xue Qin
Caruana, Michael
Soerjomataram, Isabelle
Bray, Freddie
Lawrance, Sheena
Arcorace, Maria
O’Connell, Dianne L.
Canfell, Karen
Feletto, Eleonora
Article History
Received: 5 November 2021
Accepted: 24 February 2022
First Online: 7 March 2022
Competing interests
: KC is co-PI of an investigator-initiated trial of cervical screening, Compass, run by the Australian Centre for Prevention of Cervical Cancer (ACPCC), which is a government-funded not-for-profit charity; the ACPCC has received equipment and a funding contribution from Roche Molecular Diagnostics, and operational support from the Australian Government. She is also co-PI on a major investigator-initiated implementation program Elimination of Cervical Cancer in the Western Pacific (ECCWP) which will receive support from the Minderoo Foundation, the Frazer Family Foundation and equipment donations from Cepheid Inc. Neither Karen Canfell nor her institution on her behalf receives direct funding from industry for any project. No other conflicts of interest are declared.MC is an investigator on an investigator-initiated trial of cytology and primary HPV screening in Australia (‘Compass’) (ACTRN12613001207707 and NCT02328872), which is conducted and funded by the Australian Centre for the Prevention of Cervical Cancer, a government-funded health promotion charity. Australian Centre for the Prevention of Cervical Cancer has received equipment and a funding contribution for the Compass trial from Roche Molecular Systems and operational support from the Australian Government. However neither MC nor his institution on his behalf (the Daffodil Centre, a joint venture between Cancer Council NSW and The University of Sydney) receive direct or indirect funding from industry for Compass Australia or any other project. No other conflicts of interest are declared.The rest of the authors declare that they have no conflicts of interest.